FCM
SGMO

Frontier Capital Management’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Frontier Capital Management’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-178,136
Closed -$2.78M – 300
2020
Q4 		$2.78M Sell
178,136
-23,586
-12% -$276K 0.02% 275
2020
Q3 		$1.91M Sell
201,722
-17,152
-8% -$186K 0.02% 281
2020
Q2 		$1.96M Sell
218,874
-24,798
-10% -$230K 0.02% 282
2020
Q1 		$1.55M Sell
243,672
-5,287
-2% -$39.2K 0.02% 266
2019
Q4 		$2.08M Sell
248,959
-25,949
-9% -$239K 0.02% 268
2019
Q3 		$2.49M Sell
274,908
-19,540
-7% -$219K 0.02% 267
2019
Q2 		$3.17M Sell
294,448
-120,808
-29% -$1.28M 0.02% 274
2019
Q1 		$3.96M Sell
415,256
-28,130
-6% -$287K 0.03% 271
2018
Q4 		$5.09M Sell
443,386
-7,770
-2% -$96.5K 0.04% 260
2018
Q3 		$7.65M Sell
451,156
-16,225
-3% -$247K 0.05% 253
2018
Q2 		$6.64M Sell
467,381
-8,007
-2% -$133K 0.05% 254
2018
Q1 		$9.03M Sell
475,388
-2,338
-0.5% -$50K 0.07% 244
2017
Q4 		$7.83M Sell
477,726
-10,062
-2% -$150K 0.06% 241
2017
Q3 		$7.32M Sell
487,788
-7,240
-1% -$80K 0.05% 253
2017
Q2 		$4.36M Sell
495,028
-4,775
-1% -$30.6K 0.03% 273
2017
Q1 		$2.6M Sell
499,803
-9,329
-2% -$37.4K 0.02% 282
2016
Q4 		$1.55M Sell
509,132
-4,944
-1% -$18K 0.01% 278
2016
Q3 		$2.38M Buy
514,076
+146
+0% +$743 0.02% 283
2016
Q2 		$2.98M Sell
513,930
-313,637
-38% -$2M 0.02% 279
2016
Q1 		$5.01M Sell
827,567
-2,084
-0.3% -$12.5K 0.04% 270
2015
Q4 		$7.58M Sell
829,651
-253,136
-23% -$1.95M 0.06% 265
2015
Q3 		$6.11M Sell
1,082,787
-818,817
-43% -$6.75M 0.05% 274
2015
Q2 		$21.1M Sell
1,901,604
-265,371
-12% -$3.42M 0.15% 203
2015
Q1 		$34M Buy
2,166,975
+305,417
+16% +$4.73M 0.25% 154
2014
Q4 		$28.3M Sell
1,861,558
-290,621
-14% -$3.53M 0.21% 165
2014
Q3 		$23.2M Sell
2,152,179
-70,216
-3% -$917K 0.19% 179
2014
Q2 		$33.9M Buy
2,222,395
+905,205
+69% +$13M 0.25% 144
2014
Q1 		$23.8M Buy
+1,317,190
New +$25.4M 0.17% 181

Other funds holding SGMO

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Frontier Capital Management's SGMO Position: Q1 2021 in Review

Frontier Capital Management sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q1 2021, closing a stake of 178,136 shares — an estimated $2.78M sold.

Frontier Capital Management first reported a position in SGMO in Q1 2014 and held it in 28 quarters. The position peaked at $34M in Q1 2015. 203 funds tracked by Wall St. Rank hold SGMO as of Q1 2021.

  • Frontier Capital Management reported no remaining SANGAMO THERAPEUTICS INC position as of Q1 2021 after selling out during the quarter.
  • Frontier Capital Management sold 178,136 SANGAMO THERAPEUTICS INC shares in Q1 2021, an estimated $2.78M.
  • Frontier Capital Management first reported a position in SANGAMO THERAPEUTICS INC in Q1 2014 and held it in 28 quarters.
  • Frontier Capital Management's SANGAMO THERAPEUTICS INC position peaked at $34M in Q1 2015.
  • 203 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2021.

Based on Frontier Capital Management's 13F filing for Q1 2021, filed 13 May 2021.